Amgen wins recommendation for single injection Repatha device

Amgen (NSDQ:AMGN) said today that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion for its Repatha single monthly injection device. The device is already cleared in Europe for dosing every 2 weeks.

The hands-free device, with prefilled cartridges, delivers 420 milligrams of Repatha (evolocumab) in a single injection. Repatha, a human monoclonal antibody, inhibits a protein which is responsible for blocking the body’s system that naturally eliminates low-density lipoprotein cholesterol.

Get the full story at our sister site, Drug Delivery Business News.

The post Amgen wins recommendation for single injection Repatha device appeared first on MassDevice.

from MassDevice http://ift.tt/2h2HuH8